RankAlpha logo
Back to Rankings

CCCC

C4 TherapeuticsC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
Operationally, the story has improved since the prior baseline: MOMENTUM has started, the elranatamab combination trial has dosed its first patient, and Roche added a fresh collaboration with upfront cash and milestone optionality. For a company with a market cap near $286 million, those are real execution markers rather than hypothetical roadmap items.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +8.8.
What can break
As of May 8, 2026, no confirmed Q1 2026 earnings release or 10-Q was found in recent company IR postings or SEC recent filings, leaving an important cash-burn and quarterly-update gap.
Momentum
79
Value
41
Sentiment
36
Setup hits (3d)
— · Net —
AI TargetsBase $3.10 · Bull $5.00 · Bear $1.70
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net —
Target $13.33
Why
Momentum79 · Δ7d +8.8
Value41 · Δ7d -0.1
Sentiment36 · Δ7d +5.6
So what
Balanced signals. Wait for confirmation before sizing up.
Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits
Lead driver: Momentum · See technicals
Momentum
79
26% active weight
Current posture
7d trendImproving
Δ7d
+8.8
Δ21d
-3.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
36
34% active weight
Current posture
7d trendImproving
Δ7d
+5.6
Δ21d
+10.0
Why this grade

Composite grade C. Momentum 79.0 / Value 41.1 / Sentiment 36.2

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$407.99M
Beta
2.97
Shares Out
110.57M
P/E (TTM) · Derived
-2.9
P/S (TTM)
6.53
P/FCF (TTM) · Derived
-3.56
Rev YoY
-15.0%
EPS YoY
-46.4%
Gross Margin
+77.7%
Op Margin
-431.1%
Net Debt
-$188.56M
Current Ratio
9.00
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology